Xiang lab - Front Immunol paper

The 41BB-agonist potentiates the therapeutic efficacy of a combined irreversible electroporation ablation treatment of lung cancer by promoting unexpected CD8+CD103+ cDC1 and tissue-resident memory T cell responses

Fang C, Wu Z, Leary SC, Bai Y, Yu M, Baniak N, Ahmed S, Groot G, Moser M, Zhang W, Zhang B, Huang J, Ma H, Feng Y, Xiang J. Front Immunol. 2025 Oct 21;16:1688281. doi: 10.3389/fimmu.2025.1688281. eCollection 2025. PMID: 41194931